Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies

Table 1 Summary of included studies

Author, Year	Design	Quality	Observed patients		Mortality	HR (95% CI)
Author, Year	Design	Quality	recruitment	no	Mortality	HR (95% CI)
Søyseth ’07 [10]	Retro	7	Post exacerbation	854	All	0.57 (0.38-0.87)
Gestel ’08 [11]	Pro	8	Post arterial surgery	1310	All	0.67 (0.52-0.86)
Gestel ’09 [12]					Cancer	0.57 (0.32-1.01)
Rutten ’10 [13]	Retro	6	Population based	2230	All	0.83 (0.65-1.08)
Short ’11 [14]	Retro	6	Post COPD admission	5977	All	0.89 (0.81-0.97)
Bartziokas ’11 [15]	Pro	8	Post exacerbation	245	All	0.85 (0.27-2.69)
Lawes ’12 [16]	Retro	7	Post COPD admission	1687	All	0.69 (0.58-0.84)
Young ’13 [16, 17]	Retro	7	Post COPD admission	1687	Resp	0.55 (0.43-0.78)
Sheng ’12 [18]	Retro	7	Population based Primary prevention	1274	All	0.61 (0.43-0.85)
					CV	0.90 (0.35-2.34)
Sheng ’12 [18]	Retro	7	Population based Secondary prevention	443	All	0.58 (0.35-0.97)
					CV	0.32 (0.13-0.77)
Ekström ’13 [19]	Pro	6	Population based On long-term oxygen therapy	2249	All	0.86 (0.72-1.03)

Pro: prospective cohort study. Retro: retrospective cohort study. Quality: higher score indicates better quality and 8 is the maximum score.
All: all-cause mortality. Cancer: cancer-related mortality. CV: cardiovascular-related mortality. Resp: respiratory-related mortality.
Gestel reported two studies using a same cohort. Lawes and Young reported a same cohort.

ISSN: 1465-993X